Game-changing cholesterol-buster further reduces heart attack, stroke April 16, 2017 By Tracey Walker A new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%. Are PCSK9 inhibitors too pricey? August 19, 2016 By Christine Blank PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study. FDA approves first once-monthly injection to lower cholesterol July 15, 2016 By Christine Blank FDA approved evolocumab (Repatha, Amgen) Pushtronex system, the first monthly single-dose injection of a PCSK9 inhibitor. Repatha was already approved by FDA as the only PCSK9 inhibitor with a monthly dose last August. PCSK9 inhibitor benefits patients with statin intolerance April 08, 2016 By Tracey Walker PCSK9 inhibitor benefits patients with statin intolerance Top ways you can impact drug spending February 03, 2016 By Marc O’Connor How at-risk negotiations with pharmaceutical manufacturers and medication adherence programs improve both sides of the healthcare value equation: patient outcomes and costs. Watch list 2016: Top therapeutic areas November 30, 2015 Experts say you should follow these 6 therapeutic areas. How Express Scripts will manage pricey cholesterol drugs October 07, 2015 By Christine Blank After much criticism on the price of 2 new cholesterol-lowering drugs, Praluent and Repatha, Express Scripts said this week it will now include both drugs in its National Preferred Formulary. FDA approves major cholesterol drug August 28, 2015 By Christine Blank The FDA on August 27 approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. PCSK9 inhibitor approved for lowering cholesterol FDA has approved evolocumab (Repatha, Amgen) injection, a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), for some patients who are not able to adequately control low-density lipoprotein (LDL) cholesterol with current therapies.